David Lennon, Ph.D.
Also at AADI
About
Dr. Lennon, now serving as President and CEO at AADI since October 2, 2023 , brings an extensive background in biotechnology and pharmaceuticals spanning over 20 years. He has held pivotal roles at renowned companies, including more than 15 years at Novartis where he led innovative projects such as the development and launch of the first systemic gene therapy for spinal muscular atrophy.
Before joining AADI, he spearheaded Satellite Bio as Chief Executive Officer from July 2021 to September 2023, further building his reputation as a transformational leader in the life sciences industry. His earlier career included a significant tenure at McKinsey & Company and foundational roles in scientific research, where he contributed to advancements in genomic stability and cancer prevention.
This impressive blend of scientific acumen and executive leadership underpins his role at AADI, where he is expected to drive strategic growth and innovation in precision therapies. His comprehensive career path and academic credentials, including his studies in biophysics and molecular medicine, underscore a commitment to excellence and impactful leadership in the evolving field of biotechnology.
$AADI Performance Under David Lennon, Ph.D.
Past Roles
Fixed Compensation
Performance Compensation
Annual Bonus
Discretionary Bonus
- Additional bonus amounts may be awarded at the discretion of the Board or its compensation committee.
- No further details on performance metrics, thresholds, targets, vesting schedules, or evaluation were provided in the documents.